Related Experiment Videos
Campylobacter pylori in upper digestive tract diseases in children
Insights
Campylobacter pylori bacteria are frequently found in children with chronic abdominal pain, gastritis, and duodenal ulcers. De Nol therapy showed effectiveness in eradicating this bacteria.
Area of Science:
- Gastroenterology
- Microbiology
Background:
- Campylobacter pylori (now known as Helicobacter pylori) is implicated in gastrointestinal diseases.
- Chronic abdominal pain in children is a common condition with various etiologies.
Purpose of the Study:
- To determine the frequency of Campylobacter pylori in the gastric antrum of children with chronic abdominal pain.
- To evaluate the efficacy of De Nol therapy in eradicating Campylobacter pylori.
Main Methods:
- Flexible endoscopy and histology of antral biopsies were used for diagnosis.
- The CLO-test was employed to detect the presence of Campylobacter pylori.
- A study group of 61 children with chronic abdominal pain and a control group were analyzed.
Main Results:
- Campylobacter pylori was detected in 87.5% of children with gastritis and 75% with duodenal ulcers.
- Only 17% of the control group tested positive for Campylobacter pylori (p < 0.001).
- Four-week De Nol therapy eradicated Campylobacter pylori in 60% of children and reduced infection in 25% more.
Conclusions:
- Campylobacter pylori plays a significant role in the pathogenesis of chronic gastritis and peptic ulcer disease in children.
- De Nol demonstrates considerable efficacy in treating Campylobacter pylori infections.
Abstract:
Results of studies on the frequency of the occurrence of the bacteria, Campylobacter pylori, in the mucous membrane of the gastric antrum are presented in this paper. The study was carried out on 61 children treated for chronic abdominal pain. The diagnosis was established on the basis of flexible endoscopy and histology of antral biopsies. The presence of Campylobacter pylori was determined using the CLO-test. The positive CLO-test was obtained in 87.5% of children with gastritis, in 75% of children with duodenal ulcer and in only 17% of children from control group (p less than 0.001). Four-week therapy with De Nol eradicated Campylobacter pylori in 60% of treated children, and reduced infection in the next 25%. These bacteria seem to play an important role in the pathogenesis of chronic gastritis and peptic ulcer disease.